Today: 17 March 2026
Subscribe
Browse Category

Stock Market 23 January 2026

Meta stock jumps nearly 6% as Threads ad rollout widens and earnings loom

Meta stock jumps nearly 6% as Threads ad rollout widens and earnings loom

Meta Platforms shares jumped 5.7% to $647.63 by 9:38 a.m. ET Friday, extending a rally ahead of next week’s earnings and a Federal Reserve decision. Threads will begin global ad rollout next week, targeting over 400 million users. Britain’s Ofcom opened an investigation into Meta’s WhatsApp disclosures. Meta reports Q4 and full-year results after markets close Jan. 28.
23 January 2026
···
Robo.ai stock price jumps before the bell on Ghazi Group AI infrastructure deal (AIIO)

Robo.ai stock price jumps before the bell on Ghazi Group AI infrastructure deal (AIIO)

Robo.ai shares jumped about 25% to 33 cents in premarket trading Friday after announcing a three-year reseller deal with The Ghazi Group targeting MENA and Southeast Asia, with projected revenue over $100 million. The stock remains below Nasdaq’s $1 minimum, leaving the company at risk of delisting if it fails to regain compliance by June 8, 2026.
23 January 2026
···
Redwire stock price today: RDW jumps in premarket after 17% surge as “Golden Dome” focus returns

Redwire stock price today: RDW jumps in premarket after 17% surge as “Golden Dome” focus returns

Redwire Corp shares rose 9.9% premarket Friday after surging 17.5% Thursday, trading at $13.16. The rally follows renewed focus on the U.S. “Golden Dome” missile-defense system, with Redwire bidding for project work valued at $542 billion. H.C. Wainwright maintained its $22 price target. The company is restructuring and retiring the Edge Autonomy brand.
23 January 2026
··
Zillow stock jumps nearly 6% as fresh housing forecast lifts focus into earnings

Zillow stock jumps nearly 6% as fresh housing forecast lifts focus into earnings

Zillow Group’s Class C shares rose 5.7% Thursday and traded near $68.59 premarket Friday after the company forecast a 1.2% rise in U.S. home values and a 4.3% increase in existing-home sales for 2026. Benchmark raised its Zillow price target to $110, citing expected housing catalysts. Compass, now merged with Anywhere, is expanding private listings and seeking a legal injunction against Zillow.
23 January 2026
···
Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path

Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path

Revelation Biosciences shares rose about 2% premarket after an SEC filing showed FDA agreement on a single adaptive Phase 2/3 trial for its Gemini program in acute kidney injury. The company said strong results from roughly 300 patients could support a U.S. approval filing. Shares last traded near $0.85. Investors remain focused on trial timing and the firm’s $12.7 million cash position.
23 January 2026
··
US economic calendar today: Intel slides, Wall Street futures dip ahead of PMI and Michigan sentiment

US economic calendar today: Intel slides, Wall Street futures dip ahead of PMI and Michigan sentiment

U.S. stock futures slipped early Friday after Intel shares plunged 13.6% on a weak outlook. At 5:57 a.m. ET, S&P 500 E-minis were down 0.23%, Nasdaq 100 E-minis fell 0.35%, and Dow E-minis dropped 0.24%. Investors await key PMI data and the Michigan sentiment index later this morning. Intuitive Surgical rose 3.7% premarket after beating earnings estimates.
23 January 2026
··
Intel stock plunges in premarket, putting AI chip stocks and prices in play ahead of Big Tech earnings

Intel stock plunges in premarket, putting AI chip stocks and prices in play ahead of Big Tech earnings

Intel fell 13.6% in premarket trading after warning of supply shortages for AI data-center chips, erasing up to $31 billion in market value. Nasdaq 100 futures dropped 0.35% by 5:57 a.m. ET. Investors are watching a packed earnings week for signs that AI spending is translating into profit growth. Memory-chip prices are rising as AI infrastructure strains supply chains.
23 January 2026
··
UK stock market today: FTSE 100 slips as upbeat UK data meets rate-cut doubts; Babcock, C&C move

UK stock market today: FTSE 100 slips as upbeat UK data meets rate-cut doubts; Babcock, C&C move

The FTSE 100 fell 0.13% to 10,136.43 on Friday, reversing early gains as strong UK retail sales and a jump in business activity fueled speculation the Bank of England may delay rate cuts. Retail sales rose 0.4% in December, beating forecasts, while the UK Composite PMI hit 53.9, its highest since April 2024. Babcock shares slipped 1.2% after its CEO announced plans to retire. C&C Group dropped 9.6% on a profit warning.
23 January 2026
····
CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics shares slipped 0.5% to $60.51 in premarket trading Friday after CEO Samarth Kulkarni sold 90,000 shares for about $5.2 million under a preset plan, an SEC filing showed. The stock had surged 11.1% Thursday on heavy volume. Options trading spiked, with focus on April $90 calls. Bank of America trimmed its price target to $89 but kept a Buy rating.
23 January 2026
··
Atul Q3 results: profit jumps 40% but labour-code costs bite; shares end higher

Atul Q3 results: profit jumps 40% but labour-code costs bite; shares end higher

Atul Ltd shares rose 1.03% to 5,833.25 rupees after reporting a 40% year-on-year profit jump to 163.54 crore rupees for the December quarter, with revenue up 11% to 1,573.62 crore. Operating expenses climbed 2.9% from the previous quarter, and employee benefit costs surged due to a 41.35 crore rupee provision for new labour codes. Indian stocks closed lower, with the Nifty 50 down 0.95%.
23 January 2026
··
1 … 372 373 374 375 376 … 1,351

Stock Market Today

  • Repligen Q4 Earnings Outperform Peers in Drug Development Inputs & Services Sector
    March 16, 2026, 7:21 PM EDT. In Q4, drug development inputs & services stocks showed mixed results, with revenues surpassing estimates by 1.5%, though share prices dropped 15.6% on average. Repligen (NASDAQ:RGEN) stood out, reporting $197.9 million in revenue, an 18.1% increase year-on-year and beating analyst expectations by 2.7%. CEO Olivier Loeillot highlighted 14% organic growth led by Analytics and Proteins, exceeding revenue and operating income guidance. Despite strong top-line results, Repligen missed full-year EPS estimates, leading to a 15.7% stock decline to $114.11. The sector faces long-term growth from biologics and gene therapy investments but also pricing pressures and regulatory risks.
Go toTop